01 August 2008
The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells
Mine ErguvenABCDEFG, Nuriye AkevF, Aysegul OzdemirE, Ebru KarabulutB, Ayhan BilirABCDEFMed Sci Monit 2008; 14(8): BR165-173 :: ID: 865765
Abstract
Background
The significant roles of telomerase in carcinogenesis and drug resistance have attracted growing attention as potential therapies. The aim of the study was to investigate the effect of suramin on the telomerase activity of C6 glioma cells and on the growth of C6 glioma spheroids.
Material and Method
C6 rat glioma cells were treated with suramin at doses of 175 and 250 microM, and also with an increasing dosage for 96 hours. The effect of suramin on monolayer and spheroid cultures was determined by evaluating cell proliferation, spheroid growth, bromodeoxyuridine labeling index, changes of spheroid ultrastructure, and telomerase activity.
Results
Suramin inhibited telomerase activity in a dose-dependent manner. Suramin at 250 microM and 175 microM reduced telomerase activity and cell proliferation, spheroid growth, and bromodeoxyuridine labeling index. These groups commonly revealed distorted nuclei (i.e., nucleolus segregation at 250 microM, many vacuoles, vacuole fusions, and smoothing of the cell surface). Contrary to the effects of individually applied suramin, the increased dose of suramin increased telomerase activity but inhibited cell proliferation and bromodeoxyuridine labeling index only at the 24th and 96th hours; it inhibited spheroid growth at the 96th hour. The increased dose of the suramin-treated group showed changes of spheroid ultrastructure similar to those of the control group except for rarely observed vacuoles or vacuole fusion and microvilli.
Conclusions
To the best of our knowledge, this is the first study in the English language to show in vitro cytotoxic effect of suramin via telomerase inhibition on C6 glioma cells and spheroids.
Keywords: Telomerase - antagonists & inhibitors, Suramin - pharmacology, Spheroids, Cellular - ultrastructure, Glioma - pathology, DNA, Neoplasm - biosynthesis, Cell Nucleolus - ultrastructure, Cell Proliferation - drug effects, Tumor Cells, Cultured, Time Factors, Cell Cycle - drug effects, Bromodeoxyuridine - metabolism
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Clinical Research
Comparison of Outcomes From Sequential Endoscopic Therapy in 60 Patients With Cirrhosis and Esophagogastric...Med Sci Monit In Press; DOI: 10.12659/MSM.952290
Clinical Research
Impact of a Staged Enteral Nutrition Nursing Pathway Based on Dynamic Assessment of Tolerance and Aspiratio...Med Sci Monit In Press; DOI: 10.12659/MSM.953263
Clinical Research
Risk of Vancouver-Type AG Greater Trochanteric Periprosthetic Fractures After Cementless Total Hip Arthropl...Med Sci Monit In Press; DOI: 10.12659/MSM.952936
Clinical Research
Machine-Learning-Based Evaluation of the Prognostic Significance of the Non-High-Density Lipoprotein to Hig...Med Sci Monit In Press; DOI: 10.12659/MSM.953117
Most Viewed Current Articles
17 Jan 2024 : Review article 14,176,721
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,765,622
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,466,458
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,993
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






